Overview

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Status:
Completed
Trial end date:
2019-06-21
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and tolerability and to characterize the pharmacokinetics of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborator:
Beijing Bozhiyin T&S Co., Ltd.
Treatments:
Rotigotine